Summary
Alzheimer’s disease affects over 20 million people in Europe alone, and that figure is expected to double over the next 3 decades. The majority of people with Alzheimer’s disease have other health problems, such as cardiovascular, psychiatric and musculoskeletal diseases. This makes it even harder to diagnose and manage Alzheimer’s disease.
The aim of PROMINENT is to set up a digital platform that will improve the diagnosis and personalised treatment of people with Alzheimer’s disease coupled with other diseases. It will draw on existing artificial intelligence tools to create an open, interoperable platform capable of interacting with multiple systems to integrate diverse data from sources such as medical records, mobile devices and imaging repositories.
Advanced analytical tools embedded in the platform will highlight the most likely outcomes for individual patients, along with personalised, evidence-based suggestions for the most appropriate ways of managing the patient’s health. For clinicians, the platform will help them select the right tests and treatments for each patient. Meanwhile the platform will provide patients and care partners with personalised, relevant, easy-to-understand information on their brain health. At the same time, the platform will make it easier to assess how well treatments work in the real world. This will be particularly important as and when disease-modifying treatments for Alzheimer’s disease start to be approved and used in regular clinical practice.
While the platform will focus on Alzheimer’s disease, the project hopes that it could ultimately have an impact on the care of patients with other neurodegenerative diseases.
Achievements & News
March 2024
The papers in Frontiers in Neurology demonstrate how public-private collaborative research through IMI and now IHI is making a difference...
Participants
Show participants on mapUniversities, research organisations, public bodies, non-profit groups
- Chu Hopitaux De Bordeaux, Talence, France
- Fundacio Barcelonabeta Brain Research Center, Barcelona, Spain
- Itä-Suomen yliopisto, Kuopio, Finland
- Karolinska Institutet, Stockholm, Sweden
- Klinikum Der Universitaet Zu Koeln, Cologne, Germany
- Region Stockholm, Stockholm, Sweden
- Stichting Amsterdam Umc, Amsterdam, Netherlands
- Stiftelsen Fingers Brain Health Institute, Stockholm, Sweden
- Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden
- Synapse Research Management Partners SL, Barcelona, Spain
Patient organisations
- Alzheimer Europe, Luxembourg, Luxembourg
Third parties
- Combinostics Us Inc, Boston Ma, United States
IHI industry partners
- Bioarctic AB, Stockholm, Sweden
Contributing partners
- Combinostics Oy, Valkeakoski, Finland
Participants | |
---|---|
Name | EU funding in € |
Alzheimer Europe | 398 750 |
Chu Hopitaux De Bordeaux | 523 375 |
Fundacio Barcelonabeta Brain Research Center | 435 875 |
Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag | 357 250 |
Itä-Suomen yliopisto | 372 125 |
Karolinska Institutet | 1 811 375 |
Klinikum Der Universitaet Zu Koeln | 549 625 |
Region Stockholm | 462 125 |
Stichting Amsterdam Umc | 302 125 |
Synapse Research Management Partners SL | 555 000 |
Univerzitetni Klinicni Center Ljubljana | 302 125 |
Total Cost | 6 069 750 |